Comorbid Affective Disorders, AIDS/HIV, and Long Term Health (COBALT)
-
LEAD:
Inge Petersen -
TIMELINE:
September 2013 – August 2018 -
BUDGET:
Approx R1 500 000 -
FUNDER:
National Institutes of Health (NIH) -
PARTNERS:
University of Cape Town,
Kings College London,
World Health Organization,
University of East Anglia,
Harvard University
Outline:
The COBALT study is a cluster randomised controlled trial at the level of health clinics in the North West Province in South Africa (SA) to evaluate an intervention for HIV positive adults on antiretroviral treatment (ART) with depression. The relevance of this project to public health is that SA is home to the highest number of HIV positive people in the world and previous research indicates that depression is an important cause for non-adherence to ART. There is little evidence internationally, let alone in low resource settings, on cost-effective treatments in this patient population, or on their impact on HIV, on depression or on cardiovascular and metabolic disease outcomes.
Resources:
- Collaborative care for the detection and management of depression among adults receiving antiretroviral therapy in South Africa: study protocol for the CobALT randomised controlled trial. Lara Fairall, Inge Petersen, Babalwa Zani, Naomi Folb, Daniella Georgeu-Pepper, One Selohilwe, Ruwayda Petrus, Ntokozo Mntambo, Arvin Bhana, Carl Lombard, Max Bachmann, Crick Lund, Jill Hanass-Hancock, Daniel Chisholm, Paul McCrone, Sergio Carmona, Thomas Gaziano, Naomi Levitt, Tasneem Kathree, Graham Thornicroft, on behalf of the CobALT research team (in press March 2018)
- CobALT Poster World Bank Presentation